Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Decreased use of glucocorticoids in biological-experienced patients with rheumatoid arthritis who initiated intravenous abatacept: results from the 2-year ACTION study

R. Alten, H. Nüßlein, M. Galeazzi, HM. Lorenz, MT. Nurmohamed, WG. Bensen, GR. Burmester, HH. Peter, K. Pavelka, M. Chartier, C. Poncet, C. Rauch, Y. Elbez, M. Le Bars,

. 2016 ; 2 (1) : e000228. [pub] 20160215

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc16010835

INTRODUCTION: Prolonged glucocorticoid use may increase the risk of adverse safety outcomes, including cardiovascular events. The European League Against Rheumatism and the Canadian Rheumatology Association advise tapering glucocorticoid dose as rapidly as clinically feasible. There is a paucity of published data on RA that adequately describe concomitant treatment patterns. METHODS: ACTION (AbataCepT In rOutiNe clinical practice) is a non-interventional cohort study of patients from Europe and Canada that investigated the long-term retention of intravenous abatacept in clinical practice. We assessed concomitant glucocorticoids in patients with established RA who had participated in ACTION and received ≥1 biological agent prior to abatacept initiation. RESULTS: The analysis included 1009 patients. Glucocorticoids were prescribed at abatacept initiation in 734 (72.7%) patients at a median 7.5 mg/day dose (n=692). Of the patients who remained on abatacept at 24 months, 40.7% were able to decrease their dose of glucocorticoids, including 26.9% who decreased their dose from >5 mg/day to ≤5 mg/day. CONCLUSION: Reduction and/or cessation of glucocorticoid therapy is possible with intravenous abatacept in clinical practice.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc16010835
003      
CZ-PrNML
005      
20160520105724.0
007      
ta
008      
160408s2016 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1136/rmdopen-2015-000228 $2 doi
024    7_
$a 10.1136/rmdopen-2015-000228 $2 doi
035    __
$a (PubMed)26925253
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Alten, Rieke $u Department of Rheumatology , Schlosspark-Klinik, University Medicine , Berlin , Germany. $7 gn_A_00004908
245    10
$a Decreased use of glucocorticoids in biological-experienced patients with rheumatoid arthritis who initiated intravenous abatacept: results from the 2-year ACTION study / $c R. Alten, H. Nüßlein, M. Galeazzi, HM. Lorenz, MT. Nurmohamed, WG. Bensen, GR. Burmester, HH. Peter, K. Pavelka, M. Chartier, C. Poncet, C. Rauch, Y. Elbez, M. Le Bars,
520    9_
$a INTRODUCTION: Prolonged glucocorticoid use may increase the risk of adverse safety outcomes, including cardiovascular events. The European League Against Rheumatism and the Canadian Rheumatology Association advise tapering glucocorticoid dose as rapidly as clinically feasible. There is a paucity of published data on RA that adequately describe concomitant treatment patterns. METHODS: ACTION (AbataCepT In rOutiNe clinical practice) is a non-interventional cohort study of patients from Europe and Canada that investigated the long-term retention of intravenous abatacept in clinical practice. We assessed concomitant glucocorticoids in patients with established RA who had participated in ACTION and received ≥1 biological agent prior to abatacept initiation. RESULTS: The analysis included 1009 patients. Glucocorticoids were prescribed at abatacept initiation in 734 (72.7%) patients at a median 7.5 mg/day dose (n=692). Of the patients who remained on abatacept at 24 months, 40.7% were able to decrease their dose of glucocorticoids, including 26.9% who decreased their dose from >5 mg/day to ≤5 mg/day. CONCLUSION: Reduction and/or cessation of glucocorticoid therapy is possible with intravenous abatacept in clinical practice.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Nüßlein, Hubert $u Department of Clinical Immunology and Rheumatology , University of Erlangen-Nuremberg , Nuremberg , Germany.
700    1_
$a Galeazzi, Mauro $u Department of Rheumatology , University of Siena , Siena , Italy.
700    1_
$a Lorenz, Hanns-Martin $u Department of Rheumatology , University Hospital , Heidelberg , Germany.
700    1_
$a Nurmohamed, Michael T $u Department of Rheumatology , VU University Medical Center/Jan van Breemen Research Institute , Amsterdam , The Netherlands.
700    1_
$a Bensen, William G $u Department of Rheumatology , St Joseph's Hospital and McMaster University , Hamilton, Ontario , Canada.
700    1_
$a Burmester, Gerd R $u Department of Rheumatology and Immunology , Charité-Universitätsmedizin , Berlin , Germany.
700    1_
$a Peter, Hans-Hartmut $u Center for Chronic Immunodeficiency, University Medical Center , Freiburg , Germany.
700    1_
$a Pavelka, Karel $u Institute of Rheumatology and Clinic of Rheumatology, Charles University , Prague , Czech Republic.
700    1_
$a Chartier, Mélanie $u Department of Real-World Research , Chiltern International , Neuilly , France.
700    1_
$a Poncet, Coralie $u Department of Biostatistics , DOCS International , Nanterre , France.
700    1_
$a Rauch, Christiane $u Department of Medical Immunoscience , Bristol-Myers Squibb , Munich , Germany.
700    1_
$a Elbez, Yedid $u Excelya , Boulogne-Billancourt , France.
700    1_
$a Le Bars, Manuela $u Department of Medical Affairs , Bristol-Myers Squibb , Rueil-Malmaison , France.
773    0_
$w MED00188812 $t RMD open $x 2056-5933 $g Roč. 2, č. 1 (2016), s. e000228
856    41
$u https://pubmed.ncbi.nlm.nih.gov/26925253 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20160408 $b ABA008
991    __
$a 20160520105837 $b ABA008
999    __
$a ind $b bmc $g 1114264 $s 935203
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 2 $c 1 $d e000228 $e 20160215 $i 2056-5933 $m RMD open $n RMD Open $x MED00188812
LZP    __
$a Pubmed-20160408

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace